2,079
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Mechanisms behind diffuse idiopathic peripheral neuropathy in humans – a systematic review

, & ORCID Icon
Pages 572-582 | Received 28 Oct 2022, Accepted 13 Dec 2022, Published online: 22 Dec 2022

References

  • Roth B, Schiro DB, Ohlsson B. Diseases which cause generalized peripheral neuropathy: a systematic review. Scand J Gastroenterol. 2021;56(9):1000–1010.
  • Kamperidis N, Nightingale J. Neurological disorders and small bowel dysmotility. Curr Opin Gastroenterol. 2022;38(3):299–306.
  • Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American diabetes association. Diabetes Care. 2017;40(1):136–154.
  • Sasaki H, Kawamura N, Dyck PJ, et al. Spectrum of diabetic neuropathies. Diabetol Int. 2020;11(2):87–96.
  • DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113(10):1458–1467.
  • Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. 1983;14(2):155–167.
  • Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary sjögren’s syndrome. Reumatologia. 2018;56(2):99–105.
  • Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding parkinson disease: a case-control study. Neurology. 2009;73(21):1752–1758.
  • Themistocleous AC, Ramirez JD, Serra J, et al. The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol. 2014;14(6):368–379.
  • Schofield JR. Autonomic neuropathy-in its many guises-as the initial manifestation of the antiphospholipid syndrome. Immunol Res. 2017;65(2):532–542.
  • Oaklander AL. Immunotherapy prospects for painful small-fiber sensory neuropathies and ganglionopathies. Neurotherapeutics. 2016;13(1):108–117.
  • Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772(8):989–1003.
  • Garrison SR, Stucky CL. The dynamic TRPA1 channel: a suitable pharmacological pain target? Curr Pharm Biotechnol. 2011;12(10):1689–1697.
  • Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
  • Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
  • Tomlinson DR, Gardiner NJ. Diabetic neuropathies: components of etiology. J Peripher Nerv Syst. 2008;13(2):112–121.
  • Meldgaard T, Keller J, Olesen AE, et al. Pathophysiology and management of diabetic gastroenteropathy. Therap Adv Gastroenterol. 2019;12:1756284819852047.
  • Gonçalves NP, Vaegter CB, Andersen H, et al. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol. 2017;13(3):135–147.
  • Rahman MH, Jha MK, Suk K. Evolving insights into the pathophysiology of diabetic neuropathy: implications of malfunctioning glia and discovery of novel therapeutic targets. Curr Pharm Des. 2016;22(6):738–757.
  • Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7(11):682–690.
  • Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161(Suppl 1):S65–s86.
  • Chandrasekaran K, Anjaneyulu M, Choi J, et al. Role of mitochondria in diabetic peripheral neuropathy: influencing the NAD(+)-dependent SIRT1-PGC-1α-TFAM pathway. Int Rev Neurobiol. 2019;145:177–209.
  • Fernyhough P, McGavock J. Mechanisms of disease: mitochondrial dysfunction in sensory neuropathy and other complications in diabetes. Handb Clin Neurol. 2014;126:353–377.
  • Nazıroğlu M, Dikici DM, Dursun S. Role of oxidative stress and Ca2+ signaling on molecular pathways of neuropathic pain in diabetes: focus on TRP channels. Neurochem Res. 2012;37(10):2065–2075.
  • Jack M, Wright D. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res. 2012;159(5):355–365.
  • Ziegler D, Buchholz S, Sohr C, et al. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015;52(1):65–72.
  • Verkhratsky A, Fernyhough P. Mitochondrial malfunction and Ca2+ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium. 2008;44(1):112–122.
  • Alecu I, Tedeschi A, Behler N, et al. Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. J Lipid Res. 2017;58(1):42–59.
  • Fujita Y, Murakami T, Nakamura A. Recent advances in biomarkers and regenerative medicine for diabetic neuropathy. Int J Mol Sci. 2021;22(5):2301.
  • Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications. J Diabetes Investig. 2018;9(6):1239–1254.
  • Landowski LM, Dyck PJ, Engelstad J, et al. Axonopathy in peripheral neuropathies: mechanisms and therapeutic approaches for regeneration. J Chem Neuroanat. 2016;76(Pt A):19–27.
  • Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res. 2004;146:477–492.
  • Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13(9):924–935.
  • Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res. 2003;4(4):303–312.
  • Elzinga S, Murdock BJ, Guo K, et al. Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp Neurol. 2019;320:112967.
  • Körei AE, Istenes I, Papanas N, et al. Small-Fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology. 2016;67(1):49–57.
  • Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020;7(1):e639.
  • Koike H, Katsuno M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy. Neurol Ther. 2020;9(2):213–227.
  • Vernino S. Autoimmune autonomic disorders. Continuum (Minneap Minn). 2020;26(1):44–57.
  • Faivre-Sarrailh C, Devaux JJ. Neuro-glial interactions at the nodes of ranvier: implication in health and diseases. Front Cell Neurosci. 2013;7:196.
  • Rios JC, Melendez-Vasquez CV, Einheber S, et al. Contactin-associated protein (caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci. 2000;20(22):8354–8364.
  • Charles P, Tait S, Faivre-Sarrailh C, et al. Neurofascin is a glial receptor for the paranodin/caspr-contactin axonal complex at the axoglial junction. Curr Biol. 2002;12(3):217–220.
  • Sántha P, Dobos I, Kis G, et al. Role of gangliosides in peripheral pain mechanisms. Int J Mol Sci. 2020;21(3):1005.
  • Uncini A. A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies. Exp Neurol. 2012;235(2):513–516.
  • Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001;6(1):21–27.
  • Lehmann HC, Köhne A, Meyer zu Hörste G, et al. Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies. J Neuropathol Exp Neurol. 2007;66(4):305–312.
  • Asahchop EL, Branton WG, Krishnan A, et al. HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction. JCI Insight. 2018;3(23):e122450.
  • Galligan JJ. HIV, opiates, and enteric neuron dysfunction. Neurogastroenterol Motil. 2015;27(4):449–454.
  • Harboe M, Aseffa A, Leekassa R. Challenges presented by nerve damage in leprosy. Lepr Rev. 2005;76(1):5–13.
  • Kumar V, Sachan T, Natrajan M, et al. High resolution structural changes of schwann cell and endothelial cells in peripheral nerves across leprosy spectrum. Ultrastruct Pathol. 2014;38(2):86–92.
  • Martinez AR, Nunes MB, Nucci A, et al. Sensory neuronopathy and autoimmune diseases. Autoimmune Dis. 2012;2012:873587.
  • Cheng X, Choi JS, Waxman SG, et al. Mini-review - Sodium channels and beyond in peripheral nerve disease: modulation by cytokines and their effector protein kinases. Neurosci Lett. 2021;741:135446.
  • Hoeijmakers JG, Merkies IS, Gerrits MM, et al. Genetic aspects of sodium channelopathy in small fiber neuropathy. Clin Genet. 2012;82(4):351–358.
  • Tibbs GR, Posson DJ, Goldstein PA. Voltage-Gated ion channels in the PNS: novel therapies for neuropathic pain? Trends Pharmacol Sci. 2016;37(7):522–542.
  • Sopacua M, Hoeijmakers JGJ, Merkies ISJ, et al. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst. 2019;24(1):19–33.
  • Blesneac I, Themistocleous AC, Fratter C, et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 2018;159(3):469–480.
  • Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 2012;71(1):26–39.
  • Han C, Huang J, Waxman SG. Sodium channel Nav1.8: emerging links to human disease. Neurology. 2016;86(5):473–483.
  • Kharatmal SB, Singh JN, Sharma SS. Voltage-Gated sodium channels as therapeutic targets for treatment of painful diabetic neuropathy. Mini Rev Med Chem. 2015;15(14):1134–1147.
  • Küçükali CI, Kürtüncü M, Akçay H, et al. Peripheral nerve hyperexcitability syndromes. Rev Neurosci. 2015;26(2):239–251.
  • Gerdts J, Summers DW, Sasaki Y, et al. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci. 2013;33(33):13569–13580.
  • Sasaki Y, Engber TM, Hughes RO, et al. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. Exp Neurol. 2020;329:113252.
  • Chen YH, Sasaki Y, DiAntonio A, et al. SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. Exp Neurol. 2021;339:113636.
  • Bjornsdottir G, Ivarsdottir EV, Bjarnadottir K, et al. A PRPH splice-donor variant associates with reduced sural nerve amplitude and risk of peripheral neuropathy. Nat Commun. 2019;10(1):1777.
  • Tsuda M, Koga K, Chen T, et al. Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex. J Neurochem. 2017;141(4):486–498.
  • Landerholm ÅH, Hansson PT. Mechanisms of dynamic mechanical allodynia and dysesthesia in patients with peripheral and Central neuropathic pain. Eur J Pain. 2011;15(5):498–503.
  • Ahlawat A, Rana A, Goyal N, et al. Potential role of nitric oxide synthase isoforms in pathophysiology of neuropathic pain. Inflammopharmacology. 2014;22(5):269–278.
  • Latremoliere A, Costigan M. GCH1, BH4 and pain. Curr Pharm Biotechnol. 2011;12(10):1728–1741.
  • Klatt-Schreiner K, Valek L, Kang JS, et al. High glucosylceramides and low anandamide contribute to sensory loss and pain in parkinson’s disease. Mov Disord. 2020;35(10):1822–1833.
  • Teasell RW, Arnold JM. Alpha-1 adrenoceptor hyperresponsiveness in three neuropathic pain states: complex regional pain syndrome 1, diabetic peripheral neuropathic pain and Central pain states following spinal cord injury. Pain Res Manag. 2004;9(2):89–97.
  • Bates MG, Bourke JP, Giordano C, et al. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J. 2012;33(24):3023–3033.
  • Bianco F, Lattanzio G, Lorenzini L, et al. Novel understanding on genetic mechanisms of enteric neuropathies leading to severe gut dysmotility. Eur J Histochem. 2021;65(s1):3289.
  • Reichardt F, Chassaing B, Nezami BG, et al. Western diet induces colonic nitrergic myenteric neuropathy and dysmotility in mice via saturated fatty acid- and lipopolysaccharide-induced TLR4 signalling. J Physiol. 2017;595(5):1831–1846.
  • Roth B, Larsson E, Ohlsson B. Poor intake of vitamins and minerals is associated with symptoms among patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2022;37(7):1253–1262.
  • Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21(1):3–8.
  • Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl. 1999;173:12–24. discussion 48–52.